237 reports of this reaction
2.1% of all FARICIMAB reports
#9 most reported adverse reaction
ENDOPHTHALMITIS is the #9 most commonly reported adverse reaction for FARICIMAB, manufactured by Genentech, Inc.. There are 237 FDA adverse event reports linking FARICIMAB to ENDOPHTHALMITIS. This represents approximately 2.1% of all 11,141 adverse event reports for this drug.
Patients taking FARICIMAB who experience endophthalmitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ENDOPHTHALMITIS is a less commonly reported adverse event for FARICIMAB, but still significant enough to appear in the safety profile.
In addition to endophthalmitis, the following adverse reactions have been reported for FARICIMAB:
The following drugs have also been linked to endophthalmitis in FDA adverse event reports:
ENDOPHTHALMITIS has been reported as an adverse event in 237 FDA reports for FARICIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ENDOPHTHALMITIS accounts for approximately 2.1% of all adverse event reports for FARICIMAB, making it a notable side effect.
If you experience endophthalmitis while taking FARICIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.